We are live on ! Find out more
CELGZ

Celgene Corporation Contingent Value Rights

Delisted

CELGZ was delisted on the 29th of November, 2019.

25 hedge funds and large institutions have $2.68M invested in Celgene Corporation Contingent Value Rights in 2015 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 4 increasing their positions, 6 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more first-time investments, than exits

New positions opened: 4 | Existing positions closed: 2

9% more funds holding

Funds holding: 2325 (+2)

30% less capital invested

Capital invested by funds: $3.84M → $2.68M (-$1.16M)

33% less repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 6

Holders
25
Holders Change
+2
Holders Change %
+8.7%
% of All Funds
0.7%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
4
Increased
4
Reduced
6
Closed
2
Calls
Puts
Net Calls
Net Calls Change

CELGZ Hedge Fund Activity: Q3 2015 in Review

25 of the 3,582 institutional investors tracked by Wall St. Rank reported a position in Celgene Corporation Contingent Value Rights (CELGZ) for Q3 2015, worth a combined $2.68M — down 30% from $3.84M a quarter earlier.

Buyers outnumbered sellers: 4 funds opened new CELGZ positions and 2 closed out — a net gain of 2 holders — while 4 added to existing stakes and 6 trimmed.

The largest buyer was Birchview Capital, adding an estimated $47.8K. The largest seller was Opaleye Management, cutting an estimated $225K.

  • 25 institutional investors held Celgene Corporation Contingent Value Rights (CELGZ) as of Q3 2015, up from 23 in Q2 2015.
  • Funds reported $2.68M of Celgene Corporation Contingent Value Rights stock for Q3 2015, down 30% quarter-over-quarter.
  • 4 funds opened new Celgene Corporation Contingent Value Rights positions in Q3 2015 and 2 closed out, a net change of +2 holders.
  • The largest Celgene Corporation Contingent Value Rights buyer in Q3 2015 was Birchview Capital, an estimated $47.8K added.
  • The largest Celgene Corporation Contingent Value Rights seller in Q3 2015 was Opaleye Management, an estimated $225K sold.

Based on aggregated 13F filings for Q3 2015.